Altair appoints Dr Joel Martin president and CEO
This article was originally published in Scrip
Executive Summary
Altair Therapeutics (US), a private biopharmaceutical company developing therapeutics for respiratory diseases, has named Dr Joel Martin president and CEO. He most recently served as a partner at Forward Ventures, where he directed investments in Cellective Therapeutics (acquired by MedImmune), Hypnion (acquired by Lilly), Predix Pharmaceuticals (acquired by Epix Pharmaceuticals) and Novostent.